{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:35:49Z","timestamp":1793730949546,"version":"4.6.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,7,31]],"date-time":"2017-07-31T00:00:00Z","timestamp":1501459200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s00223-017-0307-y","type":"journal-article","created":{"date-parts":[[2017,7,31]],"date-time":"2017-07-31T00:24:31Z","timestamp":1501460671000},"page":"510-518","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Evaluation of a New Fully Automated Assay for Plasma Intact FGF23"],"prefix":"10.1007","volume":"101","author":[{"given":"Jean-Claude","family":"Souberbielle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Pri\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Liesse","family":"Piketty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anya","family":"Rothenbuhler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Delanaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Chanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0947-2226","authenticated-orcid":false,"given":"Etienne","family":"Cavalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,31]]},"reference":[{"key":"307_CR1","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1681\/ASN.2007010068","volume":"18","author":"S Liu","year":"2007","unstructured":"Liu S, Quarles LD (2007) How fibroblast growth factor 23 works. J Am Soc Nephrol 18:1637\u20131647. doi:\n                        10.1681\/ASN.2007010068","journal-title":"J Am Soc Nephrol"},{"key":"307_CR2","doi-asserted-by":"publisher","first-page":"6120","DOI":"10.1074\/jbc.C500457200","volume":"281","author":"H Kurosu","year":"2006","unstructured":"Kurosu H, Ogawa Y, Miyoshi M et al (2006) Regulation of fibroblast growth factor-23 signaling by Klotho. J Biol Chem 281:6120\u20136123. doi:\n                        10.1074\/jbc.C500457200","journal-title":"J Biol Chem"},{"key":"307_CR3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/B978-0-12-373884-4.00079-3","volume":"18","author":"WH Chong","year":"2011","unstructured":"Chong WH, Molinolo AA, Chen CC, Collins MT (2011) Tumor-induced osteomalacia. Endocr Relat Cancer 18:53\u201377. doi:\n                        10.1016\/B978-0-12-373884-4.00079-3","journal-title":"Endocr Relat Cancer"},{"key":"307_CR4","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.340.A","volume":"26","author":"TO Carpenter","year":"2001","unstructured":"Carpenter TO, Imel EA, Holm IA et al (2001) A clinician\u2019s guide to X-linked hypophosphatemia. J Bone Miner Res 26:1381\u20131388. doi:\n                        10.1002\/jbmr.340.A","journal-title":"J Bone Miner Res"},{"key":"307_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s00439-005-0026-8","volume":"118","author":"I Chefetz","year":"2005","unstructured":"Chefetz I, Heller R, Galli-Tsinopoulou A et al (2005) A novel homozygous missense mutation in FGF23 causes familial tumoral calcinosis associated with disseminated visceral calcification. Hum Genet 118:261\u2013266. doi:\n                        10.1007\/s00439-005-0026-8","journal-title":"Hum Genet"},{"key":"307_CR6","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1172\/JCI31330","volume":"117","author":"S Ichikawa","year":"2007","unstructured":"Ichikawa S, Imel EA, Kreiter ML et al (2007) A homozygous missense mutation in human Klotho causes severe tumoral calcinosis. J Clin Investig 117:2684\u20132691. doi:\n                        10.1172\/JCI31330","journal-title":"J Clin Investig"},{"key":"307_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1146\/annurev.med.051308.111339","volume":"61","author":"C Bergwitz","year":"2010","unstructured":"Bergwitz C, J\u00fcppner H (2010) Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med 61:91\u2013104. doi:\n                        10.1146\/annurev.med.051308.111339","journal-title":"Annu Rev Med"},{"key":"307_CR8","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1093\/ndt\/gft065","volume":"28","author":"CP Kovesdy","year":"2013","unstructured":"Kovesdy CP, Quarles LD (2013) Fibroblast growth factor-23: what we know, what we don\u2019t know, and what we need to know. Nephrol Dial Transplant 28:2228\u20132236. doi:\n                        10.1093\/ndt\/gft065","journal-title":"Nephrol Dial Transplant"},{"key":"307_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.290","author":"V David","year":"2015","unstructured":"David V, Martin A, Isakova T et al (2015) Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int. doi:\n                        10.1038\/ki.2015.290","journal-title":"Kidney Int"},{"key":"307_CR10","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1002\/jbmr.2870","volume":"31","author":"MS Ramnitz","year":"2016","unstructured":"Ramnitz MS, Gourh P, Goldbach-Mansky R et al (2016) Phenotypic and genotypic characterization and treatment of a cohort with familial tumoral calcinosis\/hyperostosis-hyperphosphatemia syndrome. J Bone Miner Res 31:1845\u20131854. doi:\n                        10.1002\/jbmr.2870","journal-title":"J Bone Miner Res"},{"key":"307_CR11","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/ki.2011.47","volume":"79","author":"T Isakova","year":"2011","unstructured":"Isakova T, Wahl P, Vargas GS et al (2011) Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79:1370\u20131378. doi:\n                        10.1038\/ki.2011.47","journal-title":"Kidney Int"},{"key":"307_CR12","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1210\/jc.2009-1603","volume":"95","author":"T Shimada","year":"2010","unstructured":"Shimada T, Urakawa I, Isakova T et al (2010) Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab 95:578\u2013585. doi:\n                        10.1210\/jc.2009-1603","journal-title":"J Clin Endocrinol Metab"},{"key":"307_CR13","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1373\/clinchem.2013.206649","volume":"60","author":"J Donate-Correa","year":"2014","unstructured":"Donate-Correa J, De Fuentes MM, Mora-Fern\u00e1ndez C, Navarro-Gonz\u00e1lez JF (2014) Pathophysiological implications of fibroblast growth factor-23 and Klotho and their potential role as clinical biomarkers. Clin Chem 60:933\u2013940. doi:\n                        10.1373\/clinchem.2013.206649","journal-title":"Clin Chem"},{"key":"307_CR14","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00774-011-0306-4","volume":"30","author":"Y Shimizu","year":"2012","unstructured":"Shimizu Y, Fukumoto S, Fujita T (2012) Evaluation of a new automated chemiluminescence immunoassay for FGF23. J Bone Miner Metab 30:217\u2013221. doi:\n                        10.1007\/s00774-011-0306-4","journal-title":"J Bone Miner Metab"},{"key":"307_CR15","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1210\/jc.2016-1257","volume":"101","author":"P Chanson","year":"2016","unstructured":"Chanson P, Arnoux A, Mavromati M et al (2016) Reference values for IGF-I serum concentrations: comparison of six immunoassays. J Clin Endocrinol Metab 101:3450\u20133458. doi:\n                        10.1210\/jc.2016-1257","journal-title":"J Clin Endocrinol Metab"},{"key":"307_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-016-0960-3","author":"J-CC Souberbielle","year":"2016","unstructured":"Souberbielle J-CC, Massart C, Brailly-Tabard S et al (2016) Prevalence and determinants of vitamin D deficiency in healthy French adults: the VARIETE study. Endocrine. doi:\n                        10.1007\/s12020-016-0960-3","journal-title":"Endocrine"},{"key":"307_CR17","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1515\/cclm-2013-0208","volume":"51","author":"ER Smith","year":"2013","unstructured":"Smith ER, McMahon LP, Holt SG (2013) Method-specific differences in plasma fibroblast growth factor 23 measurement using four commercial ELISAs. Clin Chem Lab Med 51:1971\u20131981. doi:\n                        10.1515\/cclm-2013-0208","journal-title":"Clin Chem Lab Med"},{"key":"307_CR18","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1007\/s00198-016-3543-5","volume":"27","author":"D El-Maouche","year":"2016","unstructured":"El-Maouche D, Dumitrescu CE, Andreopoulou P et al (2016) Stability and degradation of fibroblast growth factor 23 (FGF23): the effect of time and temperature and assay type. Osteoporos Int 27:2345\u20132353. doi:\n                        10.1007\/s00198-016-3543-5","journal-title":"Osteoporos Int"},{"key":"307_CR19","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1210\/jc.2015-3558","volume":"101","author":"SN Yuen","year":"2016","unstructured":"Yuen SN, Holly K, Luke A et al (2016) Fibroblast growth factor-23 (FGF-23) levels differ across populations by degree of industrialization. J Clin Endocrinol Metab 101:2246\u20132253. doi:\n                        10.1210\/jc.2015-3558","journal-title":"J Clin Endocrinol Metab"},{"key":"307_CR20","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1210\/jc.2012-1811","volume":"97","author":"ER Smith","year":"2012","unstructured":"Smith ER, Cai MM, McMahon LP, Holt SG (2012) Biological variability of plasma intact and C-terminal FGF23 measurements. J Clin Endocrinol Metab 97:3357\u20133365. doi:\n                        10.1210\/jc.2012-1811","journal-title":"J Clin Endocrinol Metab"},{"key":"307_CR21","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1053\/j.ajkd.2011.06.011","volume":"58","author":"JH Ix","year":"2011","unstructured":"Ix JH, Chonchol M, Laughlin GA et al (2011) Relation of sex and estrogen therapy to serum fibroblast growth factor 23, serum phosphorus, and urine phosphorus: the heart and soul study. Am J Kidney Dis 58:737\u2013745. doi:\n                        10.1053\/j.ajkd.2011.06.011","journal-title":"Am J Kidney Dis"},{"key":"307_CR22","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.kint.2016.04.024","volume":"90","author":"NA Dhayat","year":"2016","unstructured":"Dhayat NA, Ackermann D, Pruijm M et al (2016) Fibroblast growth factor 23 and markers of mineral metabolism in individuals with preserved renal function. Kidney Int 90:648\u2013657. doi:\n                        10.1016\/j.kint.2016.04.024","journal-title":"Kidney Int"},{"key":"307_CR23","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.2215\/CJN.02680310","volume":"5","author":"D Pri\u00e9","year":"2010","unstructured":"Pri\u00e9 D, Friedlander G (2010) Reciprocal control of 1,25-dihydroxyvitamin D and FGF23 formation involving the FGF23\/Klotho system. Clin J Am Soc Nephrol 5:1717\u20131722. doi:\n                        10.2215\/CJN.02680310","journal-title":"Clin J Am Soc Nephrol"},{"key":"307_CR24","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1210\/jc.2009-1671","volume":"95","author":"EA Imel","year":"2010","unstructured":"Imel EA, DiMeglio LA, Hui SL et al (2010) Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. J Clin Endocrinol Metab 95:1846\u20131850. doi:\n                        10.1210\/jc.2009-1671","journal-title":"J Clin Endocrinol Metab"},{"key":"307_CR25","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1056\/NEJMoa020881","volume":"348","author":"KB Jonsson","year":"2003","unstructured":"Jonsson KB, Zahradnik R, Larsson T et al (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656\u20131663. doi:\n                        10.1056\/NEJMoa020881","journal-title":"N Engl J Med"},{"key":"307_CR26","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1210\/jc.2005-2105","volume":"91","author":"EA Imel","year":"2006","unstructured":"Imel EA, Peacock M, Pitukcheewanont P et al (2006) Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab 91:2055\u20132061. doi:\n                        10.1210\/jc.2005-2105","journal-title":"J Clin Endocrinol Metab"},{"key":"307_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-016-0756-9","author":"WJ Yu","year":"2016","unstructured":"Yu WJ, He JW, Fu WZ et al (2016) Reports of 17 Chinese patients with tumor-induced osteomalacia. J Bone Miner Metab. doi:\n                        10.1007\/s00774-016-0756-9","journal-title":"J Bone Miner Metab"},{"key":"307_CR28","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1073\/pnas.0902006107","volume":"107","author":"R Goetz","year":"2010","unstructured":"Goetz R, Nakada Y, Hu MC et al (2010) Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci 107:407\u2013412. doi:\n                        10.1073\/pnas.0902006107","journal-title":"Proc Natl Acad Sci"},{"key":"307_CR29","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMoa0706130","volume":"359","author":"OM Guti\u00e9rrez","year":"2008","unstructured":"Guti\u00e9rrez OM, Mannstadt M, Isakova T et al (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359:584\u2013592. doi:\n                        10.1056\/NEJMoa0706130","journal-title":"N Engl J Med"},{"key":"307_CR30","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1093\/ndt\/gfp191","volume":"24","author":"G Jean","year":"2009","unstructured":"Jean G, Terrat J-C, Vanel T et al (2009) High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 24:2792\u20132796. doi:\n                        10.1093\/ndt\/gfp191","journal-title":"Nephrol Dial Transplant"},{"key":"307_CR31","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1001\/jama.2011.826","volume":"305","author":"T Isakova","year":"2011","unstructured":"Isakova T, Xie H, Yang W et al (2011) Fibroblast growth factor 23 and risks of mortality and end- stage renal disease in patients with chronic kidney disease. JAMA 305:2432\u20132439. doi:\n                        10.1001\/jama.2011.826","journal-title":"JAMA"},{"key":"307_CR32","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1093\/ndt\/gfq309","volume":"25","author":"S Seiler","year":"2010","unstructured":"Seiler S, Reichart B, Roth D et al (2010) FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant 25:3983\u20133989. doi:\n                        10.1093\/ndt\/gfq309","journal-title":"Nephrol Dial Transplant"},{"key":"307_CR33","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1681\/ASN.2010121224","volume":"22","author":"J Kendrick","year":"2011","unstructured":"Kendrick J, Cheung AK, Kaufman JS et al (2011) FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 22:1913\u20131922. doi:\n                        10.1681\/ASN.2010121224","journal-title":"J Am Soc Nephrol"},{"key":"307_CR34","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1681\/ASN.2010080894","volume":"22","author":"M Wolf","year":"2011","unstructured":"Wolf M, Molnar MZ, Amaral AP et al (2011) Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 22:956\u2013966. doi:\n                        10.1681\/ASN.2010080894","journal-title":"J Am Soc Nephrol"},{"key":"307_CR35","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.2215\/CJN.01880213","volume":"8","author":"LC Baia","year":"2013","unstructured":"Baia LC, Humalda JK, Vervloet MG et al (2013) Fibroblast growth factor 23 and cardiovascular mortality after kidney transplantation. Clin J Am Soc Nephrol 8:1968\u20131978. doi:\n                        10.2215\/CJN.01880213","journal-title":"Clin J Am Soc Nephrol"},{"key":"307_CR36","doi-asserted-by":"publisher","first-page":"286","DOI":"10.2215\/CJN.05420709","volume":"5","author":"RB Oliveira","year":"2010","unstructured":"Oliveira RB, Cancela ALE, Graciolli FG et al (2010) Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 5:286\u2013291. doi:\n                        10.2215\/CJN.05420709","journal-title":"Clin J Am Soc Nephrol"},{"key":"307_CR37","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/JCI46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul C, Amaral AP, Oskouei B et al (2011) FGF23 induces left ventricular hypertrophy. J Clin Investig 121:4393\u20134408. doi:\n                        10.1172\/JCI46122","journal-title":"J Clin Investig"},{"key":"307_CR38","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1172\/JCI61405","volume":"122","author":"V Shalhoub","year":"2012","unstructured":"Shalhoub V, Shatzen EM, Ward SC et al (2012) FGF23 neutralization improves chronic kidney disease\u2014associated hyperparathyroidism yet increases mortality. J Clin Investig 122:2543\u20132553. doi:\n                        10.1172\/JCI61405","journal-title":"J Clin Investig"},{"key":"307_CR39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1161\/CIRCULATIONAHA.114.013876","volume":"132","author":"SM Moe","year":"2015","unstructured":"Moe SM, Chertow GM, Parfrey PS et al (2015) Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. Circulation 132:27\u201339. doi:\n                        10.1161\/CIRCULATIONAHA.114.013876","journal-title":"Circulation"},{"key":"307_CR40","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1038\/ki.2009.188","volume":"76","author":"SM Moe","year":"2009","unstructured":"Moe SM, Drueke TB, Group for the KW (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of chronic kidney disease mineral and bone disorder (CKD-MBD). Kidney Int 76:S1\u2013S128. doi:\n                        10.1038\/ki.2009.188","journal-title":"Kidney Int"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00223-017-0307-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-017-0307-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-017-0307-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,14]],"date-time":"2017-10-14T05:48:03Z","timestamp":1507960083000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00223-017-0307-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,31]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["307"],"URL":"https:\/\/doi.org\/10.1007\/s00223-017-0307-y","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,31]]}}}